By Fineline Cube 
China-based Livzon Pharmaceutical Group Inc., (HKG: 1513) announced that its Category 1 chemical drug YJH-012 has received clinical trial approval from the National Medical Products Administration (NMPA) for the treatment of gout.
Drug Profile
YJH-012, co-developed with domestic firm Youjia Bio, is a small interfering RNA (siRNA) drug. It provides long-term genetic-level suppression of uric acid production, differing from traditional drugs that inhibit enzyme activity to control uric acid levels.
Innovation and Advantages
The drug offers potential advantages such as extended duration of effect from a single dose and an improved safety profile. Currently, there is no similar product approved in China for this indication.-Fineline Info & Tech